^
    Back
    Association details:
    Biomarker:AKT1 Q79K
    Cancer:Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) +
    MK-2206 (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Discov
    Title:

    A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition

    Excerpt:
    M229 cells expressing AKT1Q79K exhibited reduced sensitivity to vemurafenib alone (as compared with M229 vector) but only slightly increased sensitivity to MK2206 alone (Supplementary Fig. S9). Importantly, the combination of BRAFi + AKTi was more effective than either agent alone in reducing the clonogenic growth of M229 cells expressing AKT1Q79K.
    DOI:
    10.1158/2159-8290.CD-13-0279